Nara Organics Recalls Infant Formula Over Botulism Outbreak
Nara Organics recalls Whole Milk Organic Powdered Infant Formula amid infant botulism outbreak.
Why it matters: Legal professionals handling product liability and regulatory compliance must track this recall due to serious infant health risks and potential litigation from affected families.
- Nara Organics issues nationwide recall of infant formula sold at Target from July 2025 to June 2026.
- Three infants aged 2-5 months in California, Pennsylvania, and Washington hospitalized with botulism after consuming the formula.
- FDA and CDC recommend the recall following an outbreak involving rare, severe infant illness from Clostridium botulinum spores.
- Formula accounts for less than 1% of U.S. infant formula sales; supply shortage is not expected.
Nara Organics has initiated an urgent nationwide recall of its Whole Milk Organic Powdered Infant Formula after a multistate outbreak of infant botulism linked to the product. The recall affects formula sold exclusively in the U.S. at Target stores, Target.com, and Nara’s own site between July 2025 and June 2026. This development follows reports of three infants, aged between 2 and 5 months, who became seriously ill in California, Pennsylvania, and Washington during April and May 2026.
All three infants were hospitalized and treated with BabyBIG, the only FDA-approved therapy for infant botulism, a rare but serious condition caused by spores of Clostridium botulinum producing toxins in the immature gut. Symptoms include constipation, poor feeding, drooping eyelids, weak muscle tone, swallowing difficulties, and respiratory problems.
The FDA and CDC, working with state and local partners, identified epidemiological evidence linking the outbreak to Nara Organics’ formula and recommended the recall due to the severity of the illnesses. Consumers are advised to immediately stop using the formula, clearly label any opened containers as "DO NOT USE," and store them separately for at least a month before disposal to monitor potential symptoms.
While Nara Organics’ infant formula represents less than 1% of the U.S. market, the company emphasized its commitment to baby safety and cooperation with federal agencies to investigate the cause of contamination. The product is manufactured in Europe but sold exclusively in the United States.
For legal experts, this recall highlights critical issues in product safety, regulatory compliance, and potential liability exposure for infant health risks. Monitoring the investigation’s progress and any related enforcement actions will be essential.
By the numbers:
- 3 infants hospitalized — linked to botulism cases in April and May 2026
- July 2025 to June 2026 — timeframe of recalled product sales
- <1% — market share of Nara Organics’ infant formula in the U.S.
What's next: FDA and CDC ongoing investigation into the root cause of contamination; results from formula testing pending.